Acquired growth hormone deficiency in a girl with chronic myelogenous leukemia treated with tyrosine kinase inhibitor therapy

Pediatric Blood and Cancer

Volumn 56, Issue 4, 2011, Pages 671-673

  Hobernicht, Susan L ^a   Schweiger, Bahareh ^a   Zeitler, Philip ^a   Wang, Michael ^a   Hunger, Stephen P ^a  

^a Children's Hospital Colorado   (United States)

Author keywords

CML; Dasatinib; Growth hormone deficiency; Imatinib

Indexed keywords

ARGININE; BCR ABL PROTEIN; CALCIUM; CLONIDINE; DASATINIB; GROWTH HORMONE; HYDROCORTISONE; HYDROXYUREA; IMATINIB; RECOMBINANT GROWTH HORMONE; SOMATOMEDIN C; TETRACOSACTIDE;

ARTICLE; BODY HEIGHT; CALCIUM BLOOD LEVEL; CANCER HORMONE THERAPY; CASE REPORT; CHILD; CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; CYTOGENETICS; DISEASE ASSOCIATION; DRUG EFFICACY; FEMALE; FEVER; GROWTH HORMONE DEFICIENCY; GROWTH HORMONE RELEASE; HORMONE SUBSTITUTION; HUMAN; HUMAN CELL; KARYOTYPE 46,XX; LEUKOCYTE COUNT; NAUSEA; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; SKIN BRUISING; SOMATOSTATIN RELEASE; THROMBOCYTE COUNT; TREATMENT RESPONSE;

CHILD; DISEASES IN TWINS; FEMALE; GROWTH DISORDERS; HUMAN GROWTH HORMONE; HUMANS; LEUKEMIA, MYELOGENOUS, CHRONIC, BCR-ABL POSITIVE; PIPERAZINES; PROTEIN KINASE INHIBITORS; PYRIMIDINES; THIAZOLES;

EID: 79551622697     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.22945     Document Type: Article

References (14)

1. Ries LAG, Smith MA, Gurney JG, et al. Cancer incidence and survival among children and adolescents: United States SEER Program 1975-1995. SEER Pediatr Monogr 1999;99:46-49.
2. Kimoto T, Inoue M, Kawa K. Growth deceleration in a girl treated with imatinib. Int J Hematol 2009;89:251-252.
3. Mariani S, Giona F, Basciani S, et al. Low bone density and decrease inhibin-B/FSH ratio in a boy treated with imatinib during puberty. Lancet 2008;372:111-112.
4. Schmid H, Jaeger B, Lohse J, et al. Longitudinal growth retardation in a prepubertal girl with chronic myeloid leukemia on long-term treatment with imatinib. Haematologica 2009;94:1177-1179.
5. Berman E, Nicolaides M, Maki R, et al. Altered bone and mineral metabolism in patients receiving imatinib mesylate. N Engl J Med 2006;354:2006-2013.
6. Vandyke K, Fitter S, Dewar A, et al. Dysregulation of bone remodeling by imatinib mesylate. Blood 2010;115:766-774.
7. Vandyke K, Dewar AL, Fitter S, et al. Imatinib mesylate causes growth plate closure in vivo. Leukemia 2009;23:2155-2159.
8. Kebapcilar L, Bilgir O, Alacacioglu I, et al. Does imatinib mesylate therapy cause growth hormone deficiency? Med Princ Pract 2009;18:360-363.
9. Bougneres P, Goffin V. The growth hormone receptor in growth. Endocrinol Metab Clin N Am 2007;36:1-16.
10. Bhangoo A, Anhalt H, Rosenfeld RG. Idiopathic short stature. In: Lifshitz F, editor. Pediatric endocrinology. Growth, adrenal, sexual, thyroid, calcium, and fluid balance disorders, Vol. 2, 5th edition. New York, NY: Informa Healthcare USA; 2007. pp 54-55.
11. Anderson L, Jeftinija S, Scanes C. Growth Hormone Secretion: Molecular and Cellular Mechanisms and In Vivo Approaches. Experimental Biology and Medicine 2004;229:291-302.
12. Carter-Su C, Smit L. Signaling via JAK tyrosine kinases: Growth hormone receptor as a model system. Recent Prog Horm Res 1998;53:61-83.
13. Campell G. Growth-hormone signal transduction. J Pediatr 1997;131:PSO42-PSO45.
14. Leung W, Rose S, Zhou Y, et al. Outcomes of growth hormone replacement therapy in survivors of childhood acute lymphoblastic leukemia. J Clin Oncol 2002;20:2959-2964.